Assessing cognitive function in clinical
โ
Jennifer H. Barnett; Trevor W. Robbins; Verity C. Leeson; Barbara J. Sahakian; E
๐
Article
๐
2010
๐
Elsevier Science
๐
English
โ 435 KB
Cognitive dysfunction in schizophrenia is an important target for novel therapies. Effectively measuring the cognitive effects of compounds in clinical trials of schizophrenia could be a major barrier to drug development. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (